BRAF and Miyoshi myopathy: In the present study, we focused on the combination of the novel, oral, selective HSP90α/β inhibitor TAS-116 and RAS-RAF-MEK-ERK inhibitors in RAS-mutated or BRAF-mutated MM cells.